BioArk is The life sciences community of the canton of Valais in Switzerland! Homeland of the Pharma and Biotech manufacturing in Switzerland, BioArk gather an ecosystem of large multinationals, SMEs and start-up making our region the place to be in center of Europe. BioArk is also able to propose a technological park of 5 buidlings. With its specialised facilities and network of expertise, it enables SMEs and start-ups working in the fields of biotechnology and diagnostics to realise their business opportunities. So it is the ideal place for developing your business or for transforming your project into an industrial and commercial reality | The Valais provides a renowned and attractive ecosystem for pharmaceutical and biopharmaceutical manufacturing, making it a prominent hub in the industry. The Valais is a stimulating environment with a complete value chain, from cutting-edge research to high-quality production facilities. Thanks to its specialized infrastructure and network of skills, BioArk enables SMEs and start-ups active in biotechnology and diagnostics to successfully realize their business opportunities. They are therefore ideal locations for developing your business or transforming your project into an industrial and commercial reality. | BioArk – Empowering Biotech Innovation Through Infrastructure, Expertise, and Community BioArk is a leading life sciences technology park located in Valais, Switzerland, with campuses in Monthey and Visp. Developed and managed by The Ark Foundation, BioArk provides state-of-the-art infrastructure, specialized support services, and, most importantly, access to a dynamic and collaborative community of innovators across the life sciences value chain. BioArk is more than just a workspace—it is a growth platform where start-ups, SMEs, and established companies evolve in a supportive, high-performance ecosystem. Whether in biotech, diagnostics, medtech, or industrial biomanufacturing, BioArk helps companies transform ideas into scalable innovations and successful ventures.
AlphaOnco Swiss
The company AlphaOnco Swiss is the swiss subidiary of Nanobacterie, which is developing a cancer treatment using natural iron oxide nano-minerals called magnetosomes, which are introduced into tumors and heated using ultrasounds. We have demonstrated the efficacy of our therapy using mice bearing subcutaneous prostate mouse tumors, i.e. our treatment leads to full tumor disappearance in all treated mice without tumor regrowth at 6 months. It is also safe, due to moderate heating conditions (43°-45°) and to the use of completely natural/non-toxic nanoparticles. The treatment can be carried out in an ambulatory fashion, i.e. it does not require general anesthesia nor the use of the operation theatre, or a surgeon or radiotherapist. Beside these advantages, the therapy has a low cost of fabrication (250 euros/patient), which would potentially make it available to the large percentage of patients suffering from prostate tumors who can’t be treated today due to a too high treatment cost or a lack of access to hospitals. This technology gave birth to 40 scientific papers (ajouter lien Google Scholar Edouard Alphandéry). It is protected by 120 patents with strong IP in Europe and USA (ajouter Lens Patent Search) covering three domains: i) the magnetosomes themselves, ii) methods for producing these magnetosomes, iii) and various devices for tumor treatments with nanoparticles using heat which can be generated either by a magnetic field, laser, ultrasound, or cold, immune-stimulation, or drug release. Our project received three international Eurostars grants and continues to benefit from excellent public support due to its scientific quality and the solution that it offers to patients suffering from prostate and potentially other solid tumors. We will not limit our ambition to prostate cancer. After achieving prostate treatment, we will expand our research and therefore the scope of our therapy using magnetosomes to breast, head and neck, sarcoma, glioblastoma… For the time being we are looking for private funds in order to prepare and carry out clinical trials on patients suffering from prostate tumors. We are looking for 10 million euros in equity to reach the commercialization phase of our treatment. They could be invested in our company in one or several rounds. Two family offices and a large French company already interested by our technology are looking at investing in our project. | AlphaOnco Swiss, subsidiary of Nanobacterie, is developing a cancer treatment using natural iron oxide nano-minerals, called magnetosomes, which are introduced to tumors and heated using various excitation sources (laser, ultrasound, magnetic field).